文献速递中枢神经肿瘤放疗胸部肿瘤放疗消化道肿瘤放疗

临床正常组织淋巴细胞保护效应(LymphoTEC):免疫治疗时代减轻放射性淋巴细胞减少的剂量约束考量系统综述

Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy.
PubMed 文献 · Radiother Oncol · 2022-11-02

本文系统综述了实体恶性肿瘤中放射性淋巴细胞减少的剂量学预测因素。检索PubMed、Cochrane Central和Google Scholar至2022年5月31日,共纳入48项研究,按Newcastle-Ottawa质量评估分为好、中、差质量。来自好质量研究的剂量学参数被列为LymphoTEC剂量约束,中差质量研究的参数列为可选。肺平均剂量、心脏平均剂量、脑V25、脾平均剂量、免疫细胞估计剂量和骨髓V10是与放疗相关严重淋巴细胞减少最强的预测因素。

要点

  • 肺平均剂量、心脏平均剂量、脑V25、脾平均剂量、免疫细胞估计剂量和骨髓V10是严重淋巴细胞减少的最强预测因素。
  • 共48项研究纳入分析,涵盖中枢神经系统6项、胸部11项、消化道26项、妇科2项,头颈、乳腺和泌尿生殖系统各1项。
  • 来自好质量研究的剂量学参数被列为LymphoTEC剂量约束,中差质量研究的参数列为可选。

核心结论

  • 优化放疗照射以限制淋巴细胞丰富结构的剂量,可能遏制淋巴细胞耗竭带来的负面肿瘤学影响。
  • 本文描述的剂量约束可考虑用于前瞻性验证和未来临床试验,以限制放射性淋巴细胞减少的风险并可能改善癌症相关结局。

研究设计与样本

  • 系统综述检索PubMed、Cochrane Central和Google Scholar,关键词为「radiation」「lymphopenia」「cancer」「dosimetric predictors」,纳入截止日期为2022年5月31日。
  • 初检得到1632篇文章,最终48项研究符合预设纳入标准。
  • 研究按Newcastle-Ottawa质量评估分为好、中、差质量;好质量研究的剂量学参数列为LymphoTEC剂量约束,中差质量研究的参数列为可选。

主要发现

  • 48项研究按肿瘤部位分类:中枢神经系统6项、胸部11项、消化道26项、妇科2项、头颈、乳腺和泌尿生殖系统各1项。
  • 肺平均剂量、心脏平均剂量、脑V25、脾平均剂量、免疫细胞估计剂量和骨髓V10是与放疗相关严重淋巴细胞减少的最强预测因素之一。

关键数值与推荐

  • 来自好质量研究的剂量学参数被列为LymphoTEC剂量约束。
  • 来自中质量和差质量研究的剂量学参数被列为可选。

临床怎么用

  • 本文描述的剂量约束可考虑用于前瞻性验证和未来临床试验,以限制放射性淋巴细胞减少的风险并可能改善癌症相关结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation-related lymphopenia has been associated with suboptimal tumor control rates leading to inferior survival outcomes. To date, no standardized dose constraints are available to limit radiation dose to resident and circulating lymphocyte populations. We undertook this systemic review of the literature to provide a synopsis of the dosimetric predictors of radiation-related lymphopenia in solid malignancies. METHODOLOGY: A systematic literature review of PubMed (National Institutes of Health), Cochrane Central (Cochrane collaboration), and Google Scholar was conducted with the following keywords: "radiation", "lymphopenia", "cancer", "dosimetric predictors" with an inclusion deadline of May 31, 2022. Studies that met prespecified inclusion criteria were designated either Good, Fair, or Poor Quality based on the Newcastle-Ottawa quality assessment. The dosimetric parameters derived from Good Quality studies were tabulated as LymphoTEC dose constraints. Dosimetric parameters derived from Fair and Poor-quality studies were grouped as optional. RESULTS: An initial systematic search of the literature yielded 1,632 articles. After screening, a total of 48 studies met inclusion criteria and were divided into the following categories: central nervous system (CNS, 6), thoracic (11), gastrointestinal (26), gynecologic (2), head and neck, breast, and genitourinary (one each) cancers. Lung mean dose, heart mean dose, brain V25, spleen mean dose, estimated dose to immune cells, and bone marrow V10 were among the strongest predictors for severe lymphopenia related to radiotherapy. CONCLUSION: Optimizing the delivery of radiation therapy to limit dose to lymphocyte-rich structures may curb the negative oncologic impact of lymphocyte depletion. The dose constraints described herein may be considered for prospective validation and future use in clinical trials to limit risk of radiation-related lymphopenia and possibly improve cancer-associated outcomes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Venkatesulu B, Giridhar P, Pujari L, et al. Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. Radiother Oncol. 2022. PMID: 36334694. doi:10.1016/j.radonc.2022.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。